Advanced Cancers Clinical Trial
Official title:
The Survey About Resting Metabolic Rate and Its Related Factors in Terminal Patients
Cachectic patients often lose their appetite, lose weight, and are prone to weakness and
even death in advanced illness. Nutrition therapy is important and of concern to the
investigators in cancer patients. More than 80% of terminal cancer or advanced illness
patients get cachexia. Cachexia is a complex, multifactorial syndrome that results from a
reduction in food intake, a variety of metabolic abnormalities (including hypermetabolism)
or more often a combination of the two. Cachexia will progress with disease progression.
Cachexia or weight loss is often the major cause of death or poor quality of life.
The change of resting energy expenditure (REE) is different in various tumor types. Most
experts agree that the REE will increase in cancer cachexia syndrome. The more weight loss,
the more cachexia will occur.
Overnutrition is not beneficial in terminal patients according to the Chiu and Easson
studies. As the investigators know, few studies focus on REE in terminal patients. In this
study, samples are from a hospice palliative ward or from hospice home care patients in a
medical center in mid-Taiwan. About 100 patients will be recruited. The investigators will
analyze the relationship between REE and its related factors. After finishing the study,
they will provide more evidence for treating cachexia in terminal patients.
According to data from the Taiwanese government, cancer mortality has been the leading cause
of death in Taiwan since 1982. The trend is increasing day by day. As the people are aging
in Taiwan, the incidence of cancer will increase and it will be more important than before.
Cachectic patients often lose their appetite, lose weight, and are prone to weakness and
even death in advanced illness. Nutrition therapy is important and of concern to the
investigators in cancer patients. More than 80% of terminal cancer or advanced illness
patients get cachexia. Cachexia is a complex, multifactorial syndrome that results from a
reduction in food intake, a variety of metabolic abnormalities (including hypermetabolism)
or more often a combination of the two. Cachexia will progress with disease progression.
Cachexia or weight loss is often the major cause of death or poor quality of life.
The change of resting energy expenditure (REE) is different in various tumor types. Most
experts agree that the REE will increase in cancer cachexia syndrome. The more weight loss,
the more cachexia will occur.
Overnutrition is not beneficial in terminal patients according to the Chiu and Easson
studies. As the investigators know, few studies focus on REE in terminal patients. In this
study, samples are from a hospice palliative ward or from hospice home care patients in a
medical center in mid-Taiwan. About 100 patients will be recruited. The investigators will
analyze the relationship between REE and its related factors. After finishing the study,
they will provide more evidence for treating cachexia in terminal patients.
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01213238 -
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
|
Phase 1 | |
Recruiting |
NCT02160366 -
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
|
||
Completed |
NCT00379353 -
The Effects of Thalidomide on Symptom Clusters
|
Phase 2 | |
Completed |
NCT00903708 -
LY2275796 in Advanced Cancer
|
Phase 1 | |
Terminated |
NCT00499382 -
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
|
N/A | |
Completed |
NCT02459964 -
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
|
Phase 4 | |
Completed |
NCT01430572 -
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
|
Phase 1 | |
Completed |
NCT02561234 -
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01375114 -
The Effects of Ginseng on Cancer-Related Fatigue
|
Phase 2 | |
Completed |
NCT01454804 -
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT01201694 -
Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)
|
Phase 1 | |
Completed |
NCT02801045 -
Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient
|
N/A | |
Completed |
NCT02873975 -
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
|
Phase 2 | |
Completed |
NCT01983969 -
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02272595 -
Rational Therapeutics Based on Matched Tumor and Normal Tissue
|
||
Active, not recruiting |
NCT01999491 -
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
Recruiting |
NCT03375983 -
Plasmodium Immunotherapy for Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT02571036 -
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|
Phase 1 | |
Withdrawn |
NCT01608139 -
Study of Curcumin, Vorinostat, and Sorafenib
|
Phase 1 | |
Completed |
NCT01024166 -
Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study
|
N/A |